238 related articles for article (PubMed ID: 27235581)
1. Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis.
Santos JR; César IC; Costa MC; Ribeiro NQ; Holanda RA; Ramos LH; Freitas GJ; Paixão TA; Pianetti GA; Santos DA
Eur J Pharm Sci; 2016 Sep; 92():235-43. PubMed ID: 27235581
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
3. A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression.
Fontes AC; Bretas Oliveira D; Santos JR; Carneiro HC; Ribeiro NQ; Oliveira LV; Barcellos VA; Paixão TA; Abrahão JS; Resende-Stoianoff MA; Vainstein MH; Santos DA
Med Mycol; 2017 Feb; 55(2):203-212. PubMed ID: 27486215
[TBL] [Abstract][Full Text] [Related]
4. Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii.
Mendes FE; Oliveira LV; Faria ES; Alvarenga DG; Pinto MR; Taborda CP; Soares BM; Cisalpino PS; Santos DA
Eur J Clin Microbiol Infect Dis; 2010 Dec; 29(12):1525-32. PubMed ID: 20803047
[TBL] [Abstract][Full Text] [Related]
5. Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis.
Santos JR; Holanda RA; Frases S; Bravim M; Araujo Gde S; Santos PC; Costa MC; Ribeiro MJ; Ferreira GF; Baltazar LM; Miranda AS; Oliveira DB; Santos CM; Fontes AC; Gouveia LF; Resende-Stoianoff MA; Abrahão JS; Teixeira AL; Paixão TA; Souza DG; Santos DA
PLoS One; 2014; 9(11):e112669. PubMed ID: 25392951
[TBL] [Abstract][Full Text] [Related]
6. High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis.
Santos JRA; Ribeiro NQ; Bastos RW; Holanda RA; Silva LC; Queiroz ER; Santos DA
Sci Rep; 2017 Jul; 7(1):4661. PubMed ID: 28680034
[TBL] [Abstract][Full Text] [Related]
7. Curcumin enhances the activity of fluconazole against Cryptococcus gattii-induced cryptococcosis infection in mice.
da Silva DL; Magalhães TF; Dos Santos JR; de Paula TP; Modolo LV; de Fátima A; Buzanello Martins CV; Santos DA; de Resende-Stoianoff MA
J Appl Microbiol; 2016 Jan; 120(1):41-8. PubMed ID: 26442997
[TBL] [Abstract][Full Text] [Related]
8. In vivo development of fluconazole resistance in serial Cryptococcus gattii isolates from a cat.
Sykes JE; Hodge G; Singapuri A; Yang ML; Gelli A; Thompson GR
Med Mycol; 2017 Jun; 55(4):396-401. PubMed ID: 28339594
[TBL] [Abstract][Full Text] [Related]
9. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
10. Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii.
Ferreira GF; Santos JR; Costa MC; Holanda RA; Denadai ÂM; Freitas GJ; Santos ÁR; Tavares PB; Paixão TA; Santos DA
Antimicrob Agents Chemother; 2015 Aug; 59(8):4600-9. PubMed ID: 26014951
[TBL] [Abstract][Full Text] [Related]
11. Environmental Triazole Induces Cross-Resistance to Clinical Drugs and Affects Morphophysiology and Virulence of Cryptococcus gattii and C. neoformans.
Bastos RW; Carneiro HCS; Oliveira LVN; Rocha KM; Freitas GJC; Costa MC; Magalhães TFF; Carvalho VSD; Rocha CE; Ferreira GF; Paixão TA; Moyrand F; Janbon G; Santos DA
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109169
[No Abstract] [Full Text] [Related]
12. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
13. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii.
Chen SC; Korman TM; Slavin MA; Marriott D; Byth K; Bak N; Currie BJ; Hajkowicz K; Heath CH; Kidd S; McBride WJ; Meyer W; Murray R; Playford EG; Sorrell TC;
Clin Infect Dis; 2013 Aug; 57(4):543-51. PubMed ID: 23697747
[TBL] [Abstract][Full Text] [Related]
14. Treatment with pCramoll Alone and in Combination with Fluconazole Provides Therapeutic Benefits in
Jandú JJ; Costa MC; Santos JRA; Andrade FM; Magalhães TF; Silva MV; Castro MCAB; Coelho LCBB; Gomes AG; Paixão TA; Santos DA; Correia MTS
Front Cell Infect Microbiol; 2017; 7():211. PubMed ID: 28596945
[No Abstract] [Full Text] [Related]
15. Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11.
Yang ML; Uhrig J; Vu K; Singapuri A; Dennis M; Gelli A; Thompson GR
Antimicrob Agents Chemother; 2015 Dec; 60(3):1202-7. PubMed ID: 26643330
[TBL] [Abstract][Full Text] [Related]
16. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Vu K; Gelli A
Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin as a promising anticryptococcal agent.
Ribeiro NQ; Costa MC; Magalhães TFF; Carneiro HCS; Oliveira LV; Fontes ACL; Santos JRA; Ferreira GF; Araujo GRS; Alves V; Frases S; Paixão TA; de Resende Stoianoff MA; Santos DA
Int J Antimicrob Agents; 2017 Jun; 49(6):695-702. PubMed ID: 28450174
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil.
Andrade-Silva L; Ferreira-Paim K; Mora DJ; Da Silva PR; Andrade AA; Araujo NE; Pedrosa AL; Silva-Vergara ML
Med Mycol; 2013 Aug; 51(6):635-40. PubMed ID: 23343452
[TBL] [Abstract][Full Text] [Related]
19. Heteroresistance of Cryptococcus gattii to fluconazole.
Varma A; Kwon-Chung KJ
Antimicrob Agents Chemother; 2010 Jun; 54(6):2303-11. PubMed ID: 20385871
[TBL] [Abstract][Full Text] [Related]
20. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
Moreira IMB; Cortez ACA; de Souza ÉS; Pinheiro SB; de Souza Oliveira JG; Sadahiro A; Cruz KS; Matsuura ABJ; Melhem MSC; Frickmann H; de Souza JVB
Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35084497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
